Delivery Order SPE2DB20D1109-SPE2DB25FP53U
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $21,610.20 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on August 13, 2025, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract fulfilling pharmaceutical supply requirements for federal medical procurement. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $7,203.40 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes. The contract is a firm fixed price delivery order with an ultimate completion date of August 18, 2025, and was awarded on July 28, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued without a set-aside designation, indicating it was competitively awarded. This delivery order is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,440.70 for XOLAIR 150 mg/mL syringes under a firm fixed price contract type. The award was made on August 5, 2025, with an ultimate completion date of August 26, 2025. This delivery order represents a non-competitive, non-set-aside procurement and is being performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $4,322.04 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes on July 18, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, competitively awarded delivery order represents a non-set-aside procurement issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract is for performance at AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for XOLAIR 150 mg/ml syringes valued at $8,644.08 with a firm fixed price contract type. The delivery order is scheduled for completion by September 5, 2025, and represents a non-competitive, non-set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This...
- The Defense Logistics Agency awarded a $6,928.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of XOLAIR 300 mg/2 ml syringes. The contract, which is classified as a non-set-aside competitive award, is scheduled for completion by August 25, 2025, with performance to occur at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a discrete purchase under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a $8,644.12 firm fixed price delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes on June 16, 2025, with completion targeted for July 9, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support...
- The Defense Logistics Agency awarded a delivery order valued at $2,881.36 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes, with an ultimate completion date of August 25, 2025. This competitive award, issued on August 4, 2025, utilizes firm fixed pricing and carries no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a delivery order valued at $1,440.70 to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of August 12, 2025. This is a firm fixed price, non-set-aside contract awarded on July 22, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $3,241.54 delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a direct procurement of pharmaceutical supplies for federal medical needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP53UDelivery Order
The Defense Logistics Agency awarded a $5,762.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes, with an ultimate completion date of August 28, 2025. This non-set-aside competitive award was issued on August 7, 2025, and represents a direct order fulfillment from AmerisourceBergen's existing contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a prime vendor for the DLA Medical Supply Chain, AmerisourceBergen supplies a comprehensive portfolio of pharmaceutical products and medical devices to support military and federal healthcare systems globally. The company's demonstrated capability to fulfill federal medical procurement requirements through competitive award processes, combined with its significant IDC vehicle, positions it as a critical supplier for military healthcare pharmaceutical needs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 8/7/25 |